Status:
COMPLETED
Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease
Lead Sponsor:
University of Helsinki
Collaborating Sponsors:
Solvay Pharmaceuticals
Conditions:
Parkinson's Disease
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
The aim of the study is to assess the effect of continuous levodopa infusion on autonomic nervous system in patients with Parkinson's Disease (PD), blood pressure regulation and sweating. The investig...
Detailed Description
Parkinson's disease (PD) is one of the most common neurodegenerative disorders with increasing prevalence because of aging population. The main symptoms include rigidity, hypokinesia, tremor and impai...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson's disease: diagnosis made at least five years earlier
- Positive response to levodopa
- Motor fluctuations that cannot be adequately controlled with oral medication
- No signs or symptoms of cerebellar dysfunction or vascular parkinsonism
Exclusion
- Severe cognitive symptoms
- Glaucoma
- Severe arrythmias
- Severe asthma or COPD
- Heart, liver or kidney failure
- No significant vascular lesions in brain MRI imaging.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00914134
Start Date
April 1 2009
End Date
January 1 2011
Last Update
February 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital, Department of Neurology
Helsinki, Finland, 00250